This metabolic dependency, combined with TP5’s established roles in immunoregulation and T cell development [9,10], suggested that TP5 might function as an endogenous immunostimulant capable of reversing cancer-induced T cell dysfunction. The gene discussed is TMPO; the disease is cancer.